

# **Vaccine Supply & Implementation**

**Advisory Committee on Immunization Practices**

**June 27, 2007**

**Gregory S. Wallace , M.D., M.S., M.P.H.**

**Chief, Vaccine Supply and Assurance Branch**

**Immunization Services Division**

**National Center for Immunization and Respiratory Diseases**

**Centers for Disease Control and Prevention**



# Update on Varicella-Based Vaccine Supply

- **Varicella Zoster Virus (VZV) Bulk is used to Manufacture**
  - **Varicella Vaccine**
  - **MMR-V Vaccine**
  - **Zoster Vaccine**



# VZV Bulk Process

- Lower than Expected Yields
- Temporary Suspension of Production
- No Changes in Current Vaccine Policy Recommendations



# MMWR Notice to Readers

- **Feb 23, 2007**
  - **Prioritize production of Varicella vaccine and Zoster Vaccine**
  - **Expect depletion of MMR-V by end of 2007**
- **May 11, 2007**
  - **Expect depletion of MMR-V by end of July, 2007**



# Current MMR-V Supply

- **Orders turned off through CDC on June 6, 2007**
- **Private sector orders turned off June 15, 2007**
- **Current orders will be filled through August**



# Summary

- **No Change in recommendation for vaccination to protect against varicella disease**
- **Varicella vaccine (Varivax) supply adequate to meet needs**
- **Information on resuming MMR-V is expected later this year**



# Adolescent Vaccine Implementation

- One age cohort ~4 million adolescents
- 3 dose/one age cohort ~12 million adolescents (or ~6 million females)
- CDC contract ~50% of National total



# Public Sector Demand

Vaccine	2005	2006	2007 (through 6/15/2007)
MCV4	1.4 of 3.1 (46%)	1.7 of 4.2 (40%)	0.9 of ??
Tdap	1.1 of 4.7 (24%)	3.7 of 9.2 (41%)	1.0 of ??
HPV	---	1.1 of 2.2 (50%)	2.1 of ??

Tdap available 4 months in public sector in 2005, 6 months in private sector

HPV available 2 months in public sector in 2006, 6 months in private sector





# Adolescent Implementation Status

- Grantees purchased ~2 cohorts of Tdap in 2006, but falling off in 2007
- Grantees purchased ~1 cohort of HPV in 8 mos, yet 50% or more of the market
- Grantees purchased <1/2 cohort of MCV4 in each of the last 2.5 years



# **Adolescent Vaccine Implementation Things to Consider**

- **Adolescent Platform  $\neq$  Pediatric Vaccination (11-12 y.o. visit  $\neq$  4-6 y.o. visit)**
- **New strategies with articulated vision needed to reach adolescent goals**

